{"organizations": [], "uuid": "a71b6399211cb6d65f95abf17a990f43d37587ab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aldeyra-therapeutics-announces-agr/brief-aldeyra-therapeutics-announces-agreement-with-johnson-johnson-innovation-to-advance-novel-immune-modulating-drugs-idUSFWN1QH116", "country": "US", "domain_rank": 408, "title": "BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T15:12:00.000+02:00", "replies_count": 0, "uuid": "a71b6399211cb6d65f95abf17a990f43d37587ab"}, "author": "", "url": "https://www.reuters.com/article/brief-aldeyra-therapeutics-announces-agr/brief-aldeyra-therapeutics-announces-agreement-with-johnson-johnson-innovation-to-advance-novel-immune-modulating-drugs-idUSFWN1QH116", "ord_in_thread": 0, "title": "BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs", "locations": [], "entities": {"persons": [{"name": "johnson", "sentiment": "none"}, {"name": "janssen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-aldeyra therapeutics announces agreement with johnson & johnson", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "aldeyra therapeutics inc", "sentiment": "none"}, {"name": "advance novel immune-modulating drugs reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 14 PM / Updated 8 minutes ago BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs Reuters Staff 1 Min Read Feb 27 (Reuters) - Aldeyra Therapeutics Inc: * ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES * ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​ * ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​ * ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​ * ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-27T15:12:00.000+02:00", "crawled": "2018-02-27T15:25:22.020+02:00", "highlightTitle": ""}